Adicet Bio, Inc.
ACET- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001720580
No open-market purchases or sales by Adicet Bio, Inc. insiders were filed in the last 90 days; 56 institutions reported holding it in 13F filings for Q2 2026, worth $52.8M in total; no superinvestor holds it.
13F holders, Q2 2023
Institutional positions in Adicet Bio, Inc. as of Jun 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 95
- −12 vs. Q1 2023
- Shares held
- 37.2M
- −3.10M (−7.7%) vs. Q1 2023
- Total value
- $90.4M
- −$140.9M (−60.9%) vs. Q1 2023
- New holders
- 19
- 26 more added
- Sold out
- 31
- 32 more reduced
Compare with Q1 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ACET on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 56 | $52.8M |
| Q1 2026 | 49 | $43.7M |
| Q4 2025 | 49 | $56.6M |
| Q3 2025 | 54 | $41.6M |
| Q2 2025 | 49 | $31.5M |
| Q1 2025 | 56 | $42.0M |
| Q4 2024 | 64 | $55.4M |
| Q3 2024 | 64 | $82.3M |
| Q2 2024 | 86 | $77.4M |
| Q1 2024 | 98 | $176.6M |
| Q4 2023 | 77 | $63.0M |
| Q3 2023 | 84 | $48.9M |
| Q2 2023 | 95 | $90.4M |
| Q1 2023 | 107 | $231.3M |
| Q4 2022 | 100 | $375.7M |
| Q3 2022 | 102 | $590.7M |
| Q2 2022 | 101 | $555.9M |
| Q1 2022 | 88 | $660.4M |
| Q4 2021 | 81 | $531.2M |
| Q3 2021 | 58 | $156.1M |
| Q2 2021 | 66 | $218.1M |
| Q1 2021 | 54 | $266.3M |
Institutions, Q2 2023
Shares, value and share of portfolio for each institution holding Adicet Bio, Inc.; share changes are against Q1 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ergoteles LLC | 0 | $0 | 0.00% | −132,197−100.0% | Sold out |
| Granite Point Capital Management, L.P. | 0 | $0 | 0.00% | −65,729−100.0% | Sold out |
| Cubist Systematic Strategies, LLC | 0 | $0 | 0.00% | −49,435−100.0% | Sold out |
| Verition Fund Management LLC | 0 | $0 | 0.00% | −42,910−100.0% | Sold out |
| Skandinaviska Enskilda Banken AB (publ) | 0 | $0 | 0.00% | −42,232−100.0% | Sold out |
| Swiss National Bank | 0 | $0 | 0.00% | −41,600−100.0% | Sold out |
| BML Capital Management, LLC | 0 | $0 | 0.00% | −30,000−100.0% | Sold out |
| Balyasny Asset Management LLC | 0 | $0 | 0.00% | −27,544−100.0% | Sold out |
| Simplify Asset Management Inc. | 0 | $0 | 0.00% | −26,900−100.0% | Sold out |
| ExodusPoint Capital Management, LP | 0 | $0 | 0.00% | −23,292−100.0% | Sold out |
| Marshall Wace, LLP | 0 | $0 | 0.00% | −19,573−100.0% | Sold out |
| Point72 Asset Management, L.P. | 0 | $0 | 0.00% | −17,658−100.0% | Sold out |
| Dynamic Technology Lab Private Ltd | 0 | $0 | 0.00% | −14,662−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −13,493−100.0% | Sold out |
| Credit Suisse AG | 0 | $0 | 0.00% | −13,358−100.0% | Sold out |
| SG Americas Securities, LLC | 0 | $0 | 0.00% | −12,834−100.0% | Sold out |
| Manufacturers Life Insurance Company, The | 0 | $0 | 0.00% | −11,458−100.0% | Sold out |
| Janus Henderson Group PLC | 0 | $0 | 0.00% | −10,632−100.0% | Sold out |
| Point72 Middle East FZE | 0 | $0 | 0.00% | −9,568−100.0% | Sold out |
| Virtus ETF Advisers LLC | 0 | $0 | 0.00% | −9,506−100.0% | Sold out |
| Amundi | 0 | $0 | 0.00% | −1,836−100.0% | Sold out |
| US Bancorp | 0 | $0 | 0.00% | −1,619−100.0% | Sold out |
| Group One Trading, L.P. | 0 | $0 | 0.00% | −777−100.0% | Sold out |
| Fifth Third Bancorp | 0 | $0 | 0.00% | −142−100.0% | Sold out |
| Lindbrook Capital, LLC | 0 | $0 | 0.00% | −76−100.0% | Sold out |
| Nisa Investment Advisors, LLC | 0 | $0 | 0.00% | −22−100.0% | Sold out |